The prothrombin gene G20210A variant: prevalence in a U.K. anticoagulant clinic population

Br J Haematol. 1997 Aug;98(2):353-5. doi: 10.1046/j.1365-2141.1997.2353052.x.

Abstract

We have investigated the prevalence of a recently reported genetic variation in the prothrombin gene (G20210A) in patients with an objectively confirmed history of venous thrombosis, 12/219 patients (5.5%) were found to be heterozygous carriers of the 20210A allele. The incidence of the 20210A allele in a group of 164 healthy controls was 1.2% (allele frequency 0.61%, 95% CI 0.08-2.19). When patients with a known alternative hereditary risk factor for venous thrombosis (factor V Leiden mutation or deficiency of antithrombin, protein C or protein S) were excluded, the G20210A variant was found to increase the risk for venous thrombosis by approximately 5-fold (odds ratio 5.4, 95% CI 1.16-25.0). This prothrombin gene sequence variation adds further to the list of recognized genetic risk factors for thrombophilia.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • England / epidemiology
  • Heterozygote
  • Humans
  • Middle Aged
  • Prevalence
  • Prothrombin / genetics*
  • Thrombophlebitis / epidemiology
  • Thrombophlebitis / genetics*

Substances

  • Prothrombin